{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:24Z","timestamp":1793323344896,"version":"4.5.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI\/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI\/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240\u200amg\/dl, HDL less than 35\u200amg\/dl, triglyceride more than 200\u200amg\/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 4577 people with HIV were eligible (INSTI\u200a=\u200a66.9%, PI\/b\u200a=\u200a12.5%, and NNRTI\u200a=\u200a20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6\u20133.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0\u2013201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI\/b (adjusted incidence rate ratio 0.71; CI 0.59\u20130.85), but higher rate compared with those on NNRTI (1.35; CI 1.15\u20131.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir\/cobicistat (1.20; CI 1.00\u20131.43) and raltegravir (1.24; CI 1.02\u20131.51), but lower with rilpivirine (0.77; CI 0.63\u20130.94).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI\/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir\/cobicistat and raltegravir, but less common with rilpivirine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/qad.0000000000002811","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T17:09:08Z","timestamp":1610644148000},"page":"869-882","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":71,"title":["Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents"],"prefix":"10.1097","volume":"35","author":[{"name":"The RESPOND Study Group\u2217","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.9778\/cmajo.20180159","article-title":"Cause-specific mortality among HIV-infected people in Ontario, 1995\u20132014: a population-based retrospective cohort study","volume":"7","author":"Burchell","year":"2019","journal-title":"CMAJ Open"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","article-title":"Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort","volume":"2","author":"Croxford","year":"2017","journal-title":"Lancet Public Health"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/18734251MTAyoOTM05","article-title":"Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis from real-life data","volume":"18","author":"Grand","year":"2020","journal-title":"Curr HIV Res"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","article-title":"Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study","volume":"17","author":"Friis-M\u00f8ller","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.amjcard.2004.11.004","article-title":"Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy","volume":"95","author":"Grover","year":"2005","journal-title":"Am J Cardiol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.118.036211","article-title":"Time to recognize HIV infection as a major cardiovascular risk factor","volume":"138","author":"Hsue","year":"2018","journal-title":"Circulation"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"J Am Med Assoc"},{"key":"R8-20250608","first-page":"A45","article-title":"Incidence of elevations in the atherogenic index of plasma, a novel marker for treatment-emergent cardiovascular risk, in antiretroviral naive patients in the multicentre Canadian Observational Cohort (CANOC)","volume":"16","author":"Johns","year":"2011","journal-title":"Antivir Ther"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"e0151911","DOI":"10.1371\/journal.pone.0151911","article-title":"Antiretroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients","volume":"11","author":"Dave","year":"2016","journal-title":"PLoS One"},{"key":"R10-20250608","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004987","article-title":"Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) Trial","volume":"6","author":"Baker","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/QAD.0b013e32834917c6","article-title":"Elevated triglycerides and risk of myocardial infarction in HIV-positive persons","volume":"25","author":"Worm","year":"2011","journal-title":"AIDS"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/QAD.0b013e32834be088","article-title":"Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy","volume":"25","author":"Baker","year":"2011","journal-title":"AIDS"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0000000000002385","article-title":"Comorbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality","volume":"34","author":"Sviridov","year":"2020","journal-title":"AIDS"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2004.07.035","article-title":"Mechanism of highly active antiretroviral therapy-induced hyperlipidemia in HIV-infected individuals","volume":"178","author":"Carpentier","year":"2005","journal-title":"Atherosclerosis"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"e59514","DOI":"10.1371\/journal.pone.0059514","article-title":"HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes","volume":"8","author":"Zha","year":"2013","journal-title":"PLoS One"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Nonnucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J Hepatol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients \u2013 association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15284336.2015.1112480","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"17","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin Trials"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks","volume":"35","author":"Quercia","year":"2015","journal-title":"Clin Drug Investig"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"R24-20250608","first-page":"ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11908-020-00727-w","article-title":"Weighing in on the role of integrase strand transfer inhibitors (INSTIs) on weight gain: fact or fiction?","volume":"22","author":"P\u00e9rez","year":"2020","journal-title":"Curr Infect Dis Rep"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to nonnucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciz853","article-title":"Weight gain associated with integrase stand transfer inhibitor use in women","volume":"71","author":"Kerchberger","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","article-title":"Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"92","author":"Kuo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/microorganisms8081164","article-title":"How to RESPOND to modern challenges for people living with HIV: a profile for a new cohort consortium","volume":"8","year":"2020","journal-title":"Microorganisms"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12170-019-0597-x","article-title":"Worldwide dyslipidemia guidelines","volume":"13","author":"Bartlomiejczyk","year":"2019","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3851\/IMP3051","article-title":"Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study","volume":"21","author":"Kamara","year":"2016","journal-title":"Antivir Ther"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1124\/jpet.110.168484","article-title":"Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways","volume":"334","author":"Cao","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1","volume":"1","author":"Van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","article-title":"Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)","volume":"18","author":"Taramasso","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12981-019-0222-6","article-title":"Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice","volume":"16","author":"Gatechompol","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ecl.2014.06.003","article-title":"Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection","volume":"43","author":"Kelesidis","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","article-title":"Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines","volume":"132","author":"Moure","year":"2016","journal-title":"Antiviral Res"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/QAI.0000000000001663","article-title":"Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E\/C\/F\/TAF) in virologically suppressed women","volume":"78","author":"Hodder","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP3091","article-title":"Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity","volume":"22","author":"Funderburg","year":"2017","journal-title":"Antivir Ther"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bcpt.13161","article-title":"Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine","volume":"124","author":"Cid-Silva","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000002541","article-title":"Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV","volume":"34","author":"Lacey","year":"2020","journal-title":"AIDS"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"e0223181","DOI":"10.1371\/journal.pone.0223181","article-title":"Lipid profile changings after switching from rilpivirine\/tenofovir disoproxil fumarate\/emtricitabine to rilpivirine\/tenofovir alafenamide\/emtricitabine: different effects in patients with or without baseline hypercholesterolemia","volume":"14","author":"Taramasso","year":"2019","journal-title":"PLoS One"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/hiv.12840","article-title":"Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?","volume":"21","author":"Schwarze-Zander","year":"2020","journal-title":"HIV Med"},{"key":"R49-20250608","doi-asserted-by":"crossref","first-page":"e25083","DOI":"10.1002\/jia2.25083","article-title":"Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study","volume":"21","author":"Hatleberg","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"R50-20250608","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1089\/aid.2015.0062","article-title":"Obesity is associated with race\/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults","volume":"31","author":"Willig","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R51-20250608","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1468-1293.2007.00470.x","article-title":"Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy","volume":"8","author":"Riddler","year":"2007","journal-title":"HIV Med"},{"key":"R52-20250608","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","article-title":"Comparison of fasting and nonfasting lipid profiles in a large cohort of patients presenting at a community hospital","volume":"52","author":"Cartier","year":"2018","journal-title":"Clin Biochem"},{"key":"R53-20250608","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.117.030677","article-title":"Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy","volume":"137","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"R54-20250608","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jamainternmed.2019.0392","article-title":"Association of nonfasting vs fasting lipid levels with risk of major coronary events in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm","volume":"179","author":"Mora","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R55-20250608","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"R56-20250608","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R57-20250608","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"R58-20250608","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R59-20250608","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"R60-20250608","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"key":"R61-20250608","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1016\/S2214-109X(18)30275-4","article-title":"Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis","volume":"6","author":"Noubiap","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R62-20250608","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R63-20250608","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R64-20250608","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/QAI.0000000000002357","article-title":"Integrase strand transfer inhibitors are associated with lower risk of incident cardiovascular disease in people living with HIV","volume":"84","author":"O\u2019Halloran","year":"2020","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000002811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T20:00:46Z","timestamp":1749412846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000002811","relation":{},"ISSN":["0269-9370","1473-5571"],"issn-type":[{"value":"0269-9370","type":"print"},{"value":"1473-5571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}